Abeona Therapeutics (NASDAQ:ABEO) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Abeona Therapeutics (NASDAQ:ABEO) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.12), FiscalAI reports. The firm had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN revenue rose 31% quarter over quarter to $11.4 million, with four revenue-generating treatments recognized in the second quarter. Abeona ended June with $146.8 million in cash, cash equivalents, and short-term investments.
• The commercial rollout expanded to seven activated qualified treatment centers, and 12 patients have been treated since launch, including five in Q2 and three more in Q3 to date. The company estimates about 40% of its addressable market now has in-state access to a treatment center.
• Launch execution remains operationally complex, with scheduling disruptions, two last-minute biopsy cancellations, one low-yield batch, and one out-of-specification batch. Both affected patients were treated, but Abeona will recognize no revenue for those two treatments and said the long-term rate of non-billable units remains uncertain.
• CMS granted ZEVASKYN New Technology Add-on Payment status effective October 1, 2026, making it one of only three of 15 traditional-pathway applicants to receive the designation. Although Medicare represents roughly 10% of the payer mix, Abeona expects NTAP to improve hospital economics and potentially support broader payer negotiations.
• Abeona reported a second-quarter net loss of $20.2 million, or $0.35 per share, compared with a $17.1 million loss in Q1. Gross margin was approximately 63%, though management expects margins could reach 85%–90% at steady-state volume as fixed manufacturing costs are spread across more treatments.

Abeona Therapeutics Trading Down 5.5%

ABEO stock traded down $0.35 during midday trading on Friday, hitting $5.99. The company had a trading volume of 5,445,167 shares, compared to its average volume of 1,370,922. The stock has a market cap of $341.40 million, a price-to-earnings ratio of -5.50 and a beta of 1.35. Abeona Therapeutics has a 52 week low of $4.00 and a 52 week high of $7.65. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. The stock’s 50 day moving average price is $6.32 and its 200 day moving average price is $5.57.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, insider Madhav Vasanthavada sold 12,606 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $6.96, for a total transaction of $87,737.76. Following the completion of the sale, the insider directly owned 290,623 shares in the company, valued at approximately $2,022,736.08. The trade was a 4.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Joseph Walter Vazzano sold 39,067 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.36, for a total value of $209,399.12. Following the sale, the chief financial officer owned 518,437 shares of the company’s stock, valued at approximately $2,778,822.32. This trade represents a 7.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 281,078 shares of company stock valued at $1,709,923. 7.10% of the stock is currently owned by insiders.

Institutional Trading of Abeona Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc purchased a new stake in Abeona Therapeutics in the 2nd quarter worth $27,000. Russell Investments Group Ltd. purchased a new stake in Abeona Therapeutics in the 3rd quarter worth about $37,000. Truvestments Capital LLC lifted its stake in shares of Abeona Therapeutics by 191.4% during the 4th quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 6,770 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new position in Abeona Therapeutics in the 3rd quarter worth about $64,000. Finally, Man Group plc purchased a new stake in shares of Abeona Therapeutics in the 2nd quarter worth $67,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Trending Headlines about Abeona Therapeutics

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: ZEVASKYN net revenue increased 31% sequentially to $11.4 million in Q2 2026. Abeona treated five patients during the quarter and three more in the third quarter to date, bringing total treatments since launch to 12. Abeona Therapeutics Reports Second Quarter 2026 Results and Provides Business Update
• Positive Sentiment: The company is expanding its qualified treatment center network, which now includes seven sites nationwide. Management said more centers are progressing patients through the treatment process, supporting potential future treatment and revenue growth. Abeona also reported $146.8 million in cash, cash equivalents and short-term investments at June 30, providing financial resources to support commercialization. Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary
• Neutral Sentiment: Some commentary characterized the post-earnings sell-off as a potential buying opportunity, based on ZEVASKYN’s launch trajectory and Abeona’s cash position. However, the investment case remains dependent on the company’s ability to convert its treatment-center expansion into consistent commercial growth. Abeona Therapeutics Earnings Sell-Off Could Be a Buy Opportunity
• Negative Sentiment: Abeona reported a second-quarter loss of $0.35 per share, wider than the $0.23 consensus loss, while revenue of $11.38 million fell short of the $12.24 million analyst estimate. The weaker-than-expected results triggered the decline in ABEO shares and raised concerns about the pace of the commercial launch. Abeona Therapeutics Shares Fall After Q2 Miss

Analysts Set New Price Targets

ABEO has been the subject of a number of research reports. Oppenheimer reissued an “outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a research note on Friday. Wall Street Zen raised shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Finally, Weiss Ratings cut Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, August 3rd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $19.33.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.